The clinical picture — agitation, diaphoresis, tremor, hyperreflexia and clonus (especially lower-extremity), dilated pupils, and hyperthermia — in a patient who recently combined an SSRI with tramadol is classic for serotonin syndrome. Tramadol is a weak opioid plus a serotonin and norepinephrine reuptake inhibitor and can precipitate serotonin syndrome when added to an SSRI. The priority action is to hold both serotonergic agents and notify the provider for further management (supportive care, benzodiazepines for agitation, cyproheptadine for moderate-to-severe cases, cooling for hyperthermia). Anticholinergic toxicity (1) presents with dry skin, not diaphoresis. NMS (4) typically has lead-pipe rigidity and hyporeflexia, not hyperreflexia/clonus, and develops in patients on antipsychotics, not SSRI+tramadol.
In-depth explanation
Differentiating serotonin syndrome from its mimics is a high-yield NCLEX skill. Serotonin syndrome — neuromuscular hyperactivity (clonus, hyperreflexia, tremor), autonomic hyperactivity (diaphoresis, tachycardia, mydriasis, hyperthermia), and altered mental status (agitation, restlessness). Onset is usually within 24 hours of adding a serotonergic drug. Common combinations: SSRI/SNRI + tramadol, MAOI + SSRI/SNRI, SSRI + linezolid, SSRI + St. John's wort. Neuroleptic malignant syndrome differs by lead-pipe rigidity (not clonus), hyporeflexia, slower onset, and exposure to a dopamine antagonist (antipsychotic). Anticholinergic toxidrome differs by dry skin and absent bowel sounds — "hot, dry, blind, mad." Sympathomimetic toxicity (cocaine, amphetamine) shares hyperthermia and mydriasis but lacks clonus.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.